CClinicalTrials.gg
CompletedNCT04603456Updated Oct 29, 2020

miRNA-155 Assay Before and After Immunotherapy and Probiotics

A Phase 4 interventional study of Lacteol fort and Standardized Timothy Grass Pollen in Allergic Rhinitis, sponsored by Zagazig University. Completed at 1 site in Egypt. Open to participants aged 5 Years to 18 Years. Per ClinicalTrials.gov, last updated 2020-10-29.

Sponsored by Zagazig University · Phase 4, Interventional, and Other

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Sep 2018, registered Oct 2020).
Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
5 Years to 18 Years
Sex
All
01

Study summary

The investigators aimed to explore miRNA-155 change in response to sublingual immunotherapy (SLIT), probiotics and combined treatment with SLIT and probiotics in AR children.

Read the detailed description

Allergic rhinitis (AR) is an inflammatory state characterized by a disturbance of immunoregulatory mechanisms that leads to an amplified T helper "Th-2" response. Micro-RNAs (miRNAs) are short single-stranded RNA molecules that post transcriptionally control gene expression and can mediate allergic process. The aim of this study was to explore miRNA-155 change in response to sublingual immunotherapy (SLIT), probiotics and combined treatment with SLIT and probiotics in AR children.

02

Conditions studied

  • Allergic Rhinitis
03

In context

Rhinitis

1,105 studies on the registry are indexed under Rhinitis; 65 are open to participants now.

This study's enrollment of 45 is below the median of 89 across 906 interventional studies indexed under Rhinitis.

Browse Rhinitis studies →

Lead sponsor

Zagazig University is the lead sponsor of 447 studies on the registry; 75 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Children aged 5-18 years
  • Diagnosed as having AR
  • With positive skin test to grass pollen

Exclusion criteria

Exclusion Criteria:

  • Anatomical abnormalities of upper respiratory tract,
  • Previous immunotherapy,
  • Clinically significant inflammatory diseases,
  • Malignancies,
  • Chronic treatment with systemic corticosteroids or immune suppressive drugs
05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Probiotic Group

    consisted of 15 cases who received probiotics only. A drug called Lacteol fort (Rameda Company) . A sachet was taken once daily for three months. Each sachet contains 10 billions lactobacilli.

    Drug: Lacteol fort

  • Experimental
    SLIT Group

    included 15 children who received SLIT for 6 months. Standardized Timothy Grass Pollen (Phleum pratense)

    Drug: Standardized Timothy Grass Pollen

  • Experimental
    Combined treatment Group

    included 15 children who received probiotics and SLIT. A drug called Lacteol fort was administered A sachet was taken once daily for 3 months . Standardized Timothy Grass Pollen was taken for 6 months

    Drug: Lacteol fort and Standardized Timothy Grass Pollen

Interventions

  • DrugLacteol fort

    Lacteol fort is a drug containing lactobacilli

  • DrugStandardized Timothy Grass Pollen

    SLIT includes 2 phases build up and maintenance phases. (Jubilant HollisterStier LLC 14110 Collections Drive, Chicago USA) .

  • DrugLacteol fort and Standardized Timothy Grass Pollen

    Lacteol fort is a drug containing lactobacilli and the Standardized Timothy Grass Pollen includes 2 phases build up and maintenance phases.

06

What researchers measure

Primary outcomes

  1. Total nasal symptom score between before and after treatment

    Total Nasal Symptom Score was evaluated for the three groups at the start of the study and after 6 months. TNSS is the sum of scores for each of nasal obstruction, sneezing, nasal itching, and rhinorrhea at each time point, by means of a four-point scale (0-3) . TNSS is estimated by addition of the score for each of the symptoms to a total out of 12

    Time frame: 6 months

Secondary outcomes

  1. Serum miR-155 expression at the start and end of the study

    Serum miR-155 expression was measured for the three groups by quantitative real time PCR

    Time frame: 6 months

07

Study locations

1 site
  • Zagazig university
    Zagazig, Sharkia 44519, Egypt
08

References and documents

Publications

  • Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001 Dec;25(4):402-8. doi: 10.1006/meth.2001.1262. PubMed 11846609 ↗
  • Cox L. Sublingual immunotherapy and allergic rhinitis. Curr Allergy Asthma Rep. 2008 Apr;8(2):102-10. doi: 10.1007/s11882-008-0019-5. PubMed 18417051 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04603456
Lead sponsor
Zagazig University
Responsible party
Fedaa Nabil (Assisstant lecturer, Zagazig University) — Principal investigator
First posted
Oct 26, 2020
Start date
Sep 1, 2018
Primary completion
Mar 10, 2019
Completion
May 1, 2019
Last update
Oct 29, 2020

Study contacts

Randa Sedeek
study chair · Medical Microbiology and Immunology

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion